What drives Ipsen R&D
Leveraging our heritage for a strong future
With a deep heritage and expertise across our areas of focus, we overcome challenges along every step of the R&D pathway. We’ve been around for almost one hundred years and through focused expansion of our development pipeline, we are building momentum to be around for another hundred. We are forging life-changing external partnerships, creating great possibilities and executing a strong external innovation strategy.
We are dedicating significant firepower to identify and collaborate with external innovators in the development of new assets. With the continued performance of our commercial assets as strong growth platforms, this figure will increase.
What drives us is to make a difference. We are an organization deeply rooted in science; harnessing our expertise and collective passion we will drive innovation in Oncology, Rare Disease and Neuroscience that will deliver transformational new medicines to patients.
R&D in brief
Our R&D teams endeavor to develop innovative therapeutic solutions in our three therapeutic areas. We do this by leveraging an entrepreneurial, collaborative approach to build a sustainable portfolio and bring new treatments to patients worldwide.
Continuously investing
We invest heavily in R&D so that we can drive scientific discovery at every level. As of today, we’re accelerating over 20 innovative programs from early discovery to commercialization stage.
A portfolio that delivers success
Ipsen’s portfolio is strategically structured across our three therapeutic areas; we strengthen and expand our pipeline at every stage of development to achieve sustainable growth.
Expertise across the full pathway
Innovation is not true innovation until it has reached patients. We’re focused on bringing our pipeline to patients.
Facing challenges with resolve
Bringing high-stakes innovation to patients is never simple. But we rise to the challenge–learning through our experiences, trusting in the strength and expertise of our partnerships and using the insights we gather to move forward, creating better, faster processes for the future.
Our partnerships define who we are at Ipsen
Philippe Lopes-Fernandes, Executive Vice President, Chief Business Officer on how true collaboration paves the way to innovation.
Our acceleration defines who we are at Ipsen
Christelle Huguet, Executive Vice President, Head of Research and Development on harnessing technology to accelerate the journey from discovery to innovative medicine.
Focus areas
Ipsen has been working in oncology since 1986, and now has a portfolio that includes treatments for neuroendocrine tumor (NETs), and cancers of the kidney, liver, pancreas, thyroid, prostate and breast.
Ninety-four percent of rare medical conditions still have no treatment. We are committed to finding treatments for extremely rare bone diseases and disorders, growth disorders, rare cancers, rare liver disease and rare neurogenetic disorders.
Ipsen draws on 30 years of expertise in toxins and neuroscience research to support children and adults suffering from debilitating and degenerative neurological conditions.
